Alzinova AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, call… Read more
Alzinova AB (ALZ) - Net Assets
Latest net assets as of September 2025: Skr127.85 Million SEK
Based on the latest financial reports, Alzinova AB (ALZ) has net assets worth Skr127.85 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr136.90 Million) and total liabilities (Skr9.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr127.85 Million |
| % of Total Assets | 93.39% |
| Annual Growth Rate | 50.09% |
| 5-Year Change | 28.95% |
| 10-Year Change | 500.09% |
| Growth Volatility | 334.24 |
Alzinova AB - Net Assets Trend (2012–2024)
This chart illustrates how Alzinova AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alzinova AB (2012–2024)
The table below shows the annual net assets of Alzinova AB from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr123.82 Million | +8.75% |
| 2023-12-31 | Skr113.86 Million | +7.89% |
| 2022-12-31 | Skr105.53 Million | +19.28% |
| 2021-12-31 | Skr88.47 Million | -7.86% |
| 2020-12-31 | Skr96.02 Million | +62.45% |
| 2019-12-31 | Skr59.11 Million | -7.28% |
| 2018-12-31 | Skr63.75 Million | +116.91% |
| 2017-12-31 | Skr29.39 Million | -7.86% |
| 2016-12-31 | Skr31.90 Million | +54.60% |
| 2015-12-31 | Skr20.63 Million | +1228.93% |
| 2014-12-31 | Skr1.55 Million | +114.55% |
| 2013-12-31 | Skr723.69K | -23.61% |
| 2012-12-31 | Skr947.42K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alzinova AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19502456700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr23.45 Million | 18.94% |
| Other Components | Skr296.01 Million | 239.06% |
| Total Equity | Skr123.82 Million | 100.00% |
Alzinova AB Competitors by Market Cap
The table below lists competitors of Alzinova AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Acco Group Holdings Limited Ordinary Shares
NASDAQ:ACCL
|
$4.19 Million |
|
BQUE NATLE BELG. O.N.
F:BKB
|
$4.19 Million |
|
Tel-Instrument Electronics Corp
OTCQB:TIKK
|
$4.19 Million |
|
Tadmax Resources Berhad
KLSE:4022
|
$4.19 Million |
|
Evion Group NL
AU:EVG
|
$4.18 Million |
|
Xpedra Resources Limited
AU:XPD
|
$4.18 Million |
|
Logismos Information Systems S.A
AT:LOGISMOS
|
$4.18 Million |
|
FG Financial Group
NASDAQ:FGF
|
$4.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alzinova AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 113,858,000 to 123,823,000, a change of 9,965,000 (8.8%).
- Net loss of 20,553,000 reduced equity.
- Share repurchases of 40,171,000 reduced equity.
- New share issuances of 40,171,000 increased equity.
- Other factors increased equity by 30,518,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-20.55 Million | -16.6% |
| Share Repurchases | Skr40.17 Million | -32.44% |
| Share Issuances | Skr40.17 Million | +32.44% |
| Other Changes | Skr30.52 Million | +24.65% |
| Total Change | Skr- | 8.75% |
Book Value vs Market Value Analysis
This analysis compares Alzinova AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.97x to 0.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.66 | Skr0.64 | x |
| 2013-12-31 | Skr0.51 | Skr0.64 | x |
| 2014-12-31 | Skr0.36 | Skr0.64 | x |
| 2015-12-31 | Skr3.19 | Skr0.64 | x |
| 2016-12-31 | Skr2.91 | Skr0.64 | x |
| 2017-12-31 | Skr3.88 | Skr0.64 | x |
| 2018-12-31 | Skr5.85 | Skr0.64 | x |
| 2019-12-31 | Skr5.33 | Skr0.64 | x |
| 2020-12-31 | Skr5.45 | Skr0.64 | x |
| 2021-12-31 | Skr5.02 | Skr0.64 | x |
| 2022-12-31 | Skr4.33 | Skr0.64 | x |
| 2023-12-31 | Skr2.83 | Skr0.64 | x |
| 2024-12-31 | Skr1.85 | Skr0.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alzinova AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -68510.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-16.60%) is above the historical average (-29.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -195.83% | -84.72% | 1.96x | 1.18x | Skr-1.95 Million |
| 2013 | -46.39% | -40.00% | 0.58x | 2.01x | Skr-408.10K |
| 2014 | -30.37% | -49.41% | 0.45x | 1.38x | Skr-626.78K |
| 2015 | -16.51% | -341.28% | 0.04x | 1.08x | Skr-5.47 Million |
| 2016 | -9.29% | -56.43% | 0.16x | 1.04x | Skr-6.15 Million |
| 2017 | -8.53% | -43.31% | 0.18x | 1.08x | Skr-5.45 Million |
| 2018 | -6.57% | -44.76% | 0.14x | 1.04x | Skr-10.56 Million |
| 2019 | -10.49% | -91.09% | 0.11x | 1.07x | Skr-12.11 Million |
| 2020 | -6.77% | -43.63% | 0.15x | 1.05x | Skr-16.10 Million |
| 2021 | -8.57% | -43.79% | 0.19x | 1.04x | Skr-16.43 Million |
| 2022 | -12.38% | -78.58% | 0.15x | 1.06x | Skr-23.62 Million |
| 2023 | -14.47% | -6103.70% | 0.00x | 1.08x | Skr-27.87 Million |
| 2024 | -16.60% | -68510.00% | 0.00x | 1.08x | Skr-32.94 Million |
Industry Comparison
This section compares Alzinova AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $63,764,556
- Average return on equity (ROE) among peers: -146.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alzinova AB (ALZ) | Skr127.85 Million | -195.83% | 0.07x | $4.19 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |